VRCA - Verrica Pharmaceuticals Inc.
IEX Last Trade
0.6453
-0.005 -0.806%
Share volume: 37,063
Last Updated: Thu 26 Dec 2024 08:25:32 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$0.65
-0.01
-0.80%
Fundamental analysis
30%
Profitability
25%
Dept financing
25%
Liquidity
75%
Performance
25%
Performance
5 Days
-2.50%
1 Month
-38.21%
3 Months
-59.17%
6 Months
-90.27%
1 Year
-89.45%
2 Year
-72.67%
Key data
Stock price
$0.65
DAY RANGE
$0.62 - $0.68
52 WEEK RANGE
$0.70 - $11.41
52 WEEK CHANGE
-$90.59
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Ted White
Region: US
Website: verrica.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: verrica.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Verrica Pharmaceuticals Inc. develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; VP-103 for treating plantar warts.
Recent news